188 related articles for article (PubMed ID: 37626859)
21. Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells.
Cieri N; Greco R; Crucitti L; Morelli M; Giglio F; Levati G; Assanelli A; Carrabba MG; Bellio L; Milani R; Lorentino F; Stanghellini MT; De Freitas T; Marktel S; Bernardi M; Corti C; Vago L; Bonini C; Ciceri F; Peccatori J
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1506-14. PubMed ID: 26001696
[TBL] [Abstract][Full Text] [Related]
22. Early Post-Transplantation Serum Ferritin Level Predicts Survival in Recipients of Haploidentical Stem Cell Transplantation Using Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis.
Jullien M; Orvain C; Berceanu A; Couturier MA; Guillaume T; Peterlin P; Garnier A; Bourgeois AL; Klemencie M; Schmidt A; Hunault M; Daguindau E; Roussel X; Delepine P; Guillerm G; Giltat A; François S; Thepot S; Gouill SL; Béné MC; Chevallier P
Transplant Cell Ther; 2021 Oct; 27(10):861.e1-861.e7. PubMed ID: 34245928
[TBL] [Abstract][Full Text] [Related]
23. Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide for Primary Immunodeficiencies and Inherited Disorders in Children.
Neven B; Diana JS; Castelle M; Magnani A; Rosain J; Touzot F; Moreira B; Fremond ML; Briand C; Bendavid M; Levy R; Morelle G; Vincent M; Magrin E; Bourget P; Chatenoud L; Picard C; Fischer A; Moshous D; Blanche S
Biol Blood Marrow Transplant; 2019 Jul; 25(7):1363-1373. PubMed ID: 30876929
[TBL] [Abstract][Full Text] [Related]
24. ST2 and REG3α as Predictive Biomarkers After Haploidentical Stem Cell Transplantation Using Post-transplantation High-Dose Cyclophosphamide.
Solán L; Kwon M; Carbonell D; Dorado N; Balsalobre P; Serrano D; Chicano-Lavilla M; Anguita J; Gayoso J; Díez-Martín JL; Martínez-Laperche C; Buño I
Front Immunol; 2019; 10():2338. PubMed ID: 31649665
[TBL] [Abstract][Full Text] [Related]
25. Improved NK Cell Recovery Following Use of PTCy or Treg Expanded Donors in Experimental MHC-Matched Allogeneic HSCT.
Wolf D; Barreras H; Copsel SN; Komanduri KV; Levy RB
Transplant Cell Ther; 2022 Jun; 28(6):303.e1-303.e7. PubMed ID: 35302008
[TBL] [Abstract][Full Text] [Related]
26. Feasibility of HLA-haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for advanced pediatric malignancies.
Sawada A; Shimizu M; Isaka K; Higuchi K; Mayumi A; Yoshimoto Y; Kikuchi H; Kondo O; Koyama-Sato M; Yasui M; Kawa K; Inoue M
Pediatr Hematol Oncol; 2014 Nov; 31(8):754-64. PubMed ID: 25325678
[TBL] [Abstract][Full Text] [Related]
27. Early Myeloid Derived Suppressor Cells (eMDSCs) Are Associated With High Donor Myeloid Chimerism Following Haploidentical HSCT for Sickle Cell Disease.
Bhat DK; Olkhanud PB; Gangaplara A; Seifuddin F; Pirooznia M; Biancotto A; Fantoni G; Pittman C; Francis B; Dagur PK; Saxena A; McCoy JP; Pfeiffer RM; Fitzhugh CD
Front Immunol; 2021; 12():757279. PubMed ID: 34917079
[TBL] [Abstract][Full Text] [Related]
28. Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Fanconi Anemia: Improving Outcomes with Improved Supportive Care in India.
Uppuluri R; Swaminathan VV; Ramanan KM; Meena S; Varla H; Ramakrishnan B; Jayakumar I; Raj R
Biol Blood Marrow Transplant; 2020 Dec; 26(12):2292-2298. PubMed ID: 32835780
[TBL] [Abstract][Full Text] [Related]
29. Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies.
Law AD; Salas MQ; Lam W; Michelis FV; Thyagu S; Kim DDH; Lipton JH; Kumar R; Messner H; Viswabandya A
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2259-2264. PubMed ID: 30009980
[TBL] [Abstract][Full Text] [Related]
30. Immune Reconstitution of CD4+T Cells after Allogeneic Hematopoietic Stem Cell Transplantation and its Correlation with Invasive Fungal Infection in Patients with Hematological Malignancies.
Peng XG; Dong Y; Zhang TT; Wang K; Ma YJ
Asian Pac J Cancer Prev; 2015; 16(8):3137-40. PubMed ID: 25921110
[TBL] [Abstract][Full Text] [Related]
31. Related HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: observations of a single Chinese center.
Huang X; Liu D
Clin Transpl; 2011; ():237-45. PubMed ID: 22755417
[TBL] [Abstract][Full Text] [Related]
32. [Clinical Analysis of Efficacy and Prognosis in 300 Cases of Hematological Malignancies Receiving Allogeneic Hematopoietic Stem Cell Transplantation].
Zhang Y; Song ZY; Li YH; Lu ZG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Dec; 27(6):1979-1985. PubMed ID: 31839070
[TBL] [Abstract][Full Text] [Related]
33. Outcomes of haploidentical peripheral stem cell transplantation with combination of post-transplant cyclophosphamide (PTCy) and anti-thymocyte globulin (ATG) compared to unrelated donor transplantation in acute myeloid leukemia: A retrospective 10-year experience.
Barkhordar M; Kasaeian A; Janbabai G; Mousavi SA; Fumani HK; Tavakoli S; Bahri T; Ghavamzadeh A; Vaezi M
Leuk Res; 2022 Sep; 120():106918. PubMed ID: 35843087
[TBL] [Abstract][Full Text] [Related]
34. Clinical Utility of the Detection of the Loss of the Mismatched HLA in Relapsed Hematological Patients After Haploidentical Stem Cell Transplantation With High-Dose Cyclophosphamide.
Muñiz P; Kwon M; Carbonell D; Chicano M; Bailén R; Oarbeascoa G; Suárez-González J; Andrés-Zayas C; Menárguez J; Dorado N; Gómez-Centurión I; Anguita J; Díez-Martín JL; Martínez-Laperche C; Buño I
Front Immunol; 2021; 12():642087. PubMed ID: 33841425
[TBL] [Abstract][Full Text] [Related]
35. Post-transplant cyclophosphamide for GVHD prophylaxis in pediatrics with chronic active Epstein-Barr virus infection after haplo-HSCT.
Luo R; Zhang X; Wang Y; Man Q; Gu W; Tian Z; Wang J
Orphanet J Rare Dis; 2022 Dec; 17(1):422. PubMed ID: 36461028
[TBL] [Abstract][Full Text] [Related]
36. Comparison of clinical outcomes between unrelated single umbilical cord blood and "ex-vivo" T-cell depleted haploidentical transplantation in children with hematological malignancies.
Gómez-Santos C; González-Vicent M; Molina B; Deltoro N; Herrero B; Ruiz J; Pérez-Martínez A; Diaz MA
World J Pediatr; 2021 Dec; 17(6):609-618. PubMed ID: 34590210
[TBL] [Abstract][Full Text] [Related]
37. The Benefits of the Post-Transplant Cyclophosphamide in Both Haploidentical and Mismatched Unrelated Donor Setting in Allogeneic Stem Cells Transplantation.
Dybko J; Sobczyk-Kruszelnicka M; Makuch S; Agrawal S; Dudek K; Giebel S; Gil L
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982839
[TBL] [Abstract][Full Text] [Related]
38. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation.
Bashey A; Zhang X; Sizemore CA; Manion K; Brown S; Holland HK; Morris LE; Solomon SR
J Clin Oncol; 2013 Apr; 31(10):1310-6. PubMed ID: 23423745
[TBL] [Abstract][Full Text] [Related]
39. Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation.
Matsuoka K; Kim HT; McDonough S; Bascug G; Warshauer B; Koreth J; Cutler C; Ho VT; Alyea EP; Antin JH; Soiffer RJ; Ritz J
J Clin Invest; 2010 May; 120(5):1479-93. PubMed ID: 20389017
[TBL] [Abstract][Full Text] [Related]
40. Fludarabine and antithymocyte globulin-based conditioning regimen combined with post-transplantation cyclophosphamide for haploidentical allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia and myelodysplastic syndrome.
Cao J; Pei R; Lu Y; Zheng Z; Yuan Z; Li D; Zhang P; Liu X; Chen D; Du X; Chen L; Li S; Ye P; Wang T
Curr Res Transl Med; 2023; 71(1):103360. PubMed ID: 36427418
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
